AlfaCip represents a sophisticated formulation of ciprofloxacin hydrochloride, engineered for optimal therapeutic efficacy against a broad spectrum of gram-negative and gram-positive bacterial pathogens. This fluoroquinolone antibiotic demonstrates exceptional bioavailability and tissue penetration, making it a frontline choice for treating complicated urinary tract infections, respiratory infections, and skin structure infections. Its precision-engineered delivery system ensures consistent pharmacokinetic profiles, while its proven bactericidal activity provides clinicians with a reliable tool in antimicrobial stewardship programs.

Features

• Contains ciprofloxacin hydrochloride as active pharmaceutical ingredient
• Available in 250mg, 500mg, and 750mg film-coated tablets
• Rapid onset of action with peak serum concentrations within 1-2 hours
• Excellent tissue penetration including prostate, lung, and skin tissues
• Stable shelf life of 36 months when stored properly
• Manufactured in FDA-approved facilities following cGMP guidelines

Benefits

• Effectively eliminates susceptible bacterial pathogens through inhibition of DNA gyrase and topoisomerase IV
• Reduces infection-related complications through broad-spectrum coverage
• Minimizes treatment duration due to potent bactericidal activity
• Provides flexible dosing options for various infection severities
• Demonstrates favorable safety profile when administered appropriately
• Supports antimicrobial stewardship through targeted spectrum coverage

Common use

AlfaCip is indicated for the treatment of adults with complicated urinary tract infections, including pyelonephritis caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, Staphylococcus epidermidis, and Enterococcus faecalis. It is also prescribed for chronic bacterial prostatitis, lower respiratory tract infections, acute sinusitis, skin and skin structure infections, bone and joint infections, and infectious diarrhea. The medication may be used as empirical therapy for febrile neutropenic patients when combined with appropriate gram-positive coverage.

Dosage and direction

The recommended dosage varies based on infection severity, renal function, and pathogen susceptibility. For uncomplicated urinary tract infections: 250mg every 12 hours for 3 days. For complicated urinary tract infections and pyelonephritis: 500mg every 12 hours for 7-14 days. For respiratory infections: 500mg every 12 hours for 7-14 days. For severe infections: 750mg every 12 hours. Administration should occur at least 2 hours before or 6 hours after antacids containing magnesium or aluminum, sucralfate, didanosine, or metal cations. Tablets should be swallowed whole with a full glass of water, and patients should maintain adequate hydration during therapy. Dosage adjustment is required for patients with creatinine clearance below 30 mL/min.

Precautions

Patients should be advised that AlfaCip may cause dizziness and lightheadedness; therefore, caution should be exercised when driving or operating machinery. Tendon inflammation or rupture may occur during or after therapy, particularly in elderly patients and those receiving corticosteroid therapy. Photosensitivity reactions may develop, necessitating use of sunscreen and protective clothing during treatment. Blood glucose disturbances have been reported, requiring monitoring in diabetic patients. Peripheral neuropathy may occur and could be irreversible. Patients should report any muscle pain, tendon pain, joint swelling, or neurological symptoms immediately.

Contraindications

AlfaCip is contraindicated in patients with known hypersensitivity to ciprofloxacin or other quinolone antibiotics. Concurrent administration with tizanidine is absolutely contraindicated due to potentiated hypotensive and sedative effects. The medication should not be used in patients with history of tendon disorders related to fluoroquinolone administration. Pediatric use is generally contraindicated except for specific indications (complicated UTI and pyelonephritis) where no alternative exists. Pregnancy category C: should not be used during pregnancy unless potential benefits justify potential risks to the fetus.

Possible side effect

Common adverse reactions (≥1%) include nausea, diarrhea, vomiting, abdominal pain, headache, and restlessness. Less frequent reactions (0.1-1%) include dizziness, lightheadedness, insomnia, rash, and pruritus. Serious adverse effects include tendon rupture (particularly Achilles tendon), peripheral neuropathy, CNS effects (seizures, psychosis), QT prolongation, hepatotoxicity, and Clostridium difficile-associated diarrhea. Hematological abnormalities including leukopenia and eosinophilia may occur. Elevated liver enzymes and serum creatinine have been observed in some patients.

Drug interaction

Significant interactions occur with antacids, sucralfate, and iron preparations (reduced absorption). Concurrent use with theophylline may increase theophylline levels and toxicity. Warfarin therapy requires enhanced monitoring as prothrombin time may be prolonged. NSAIDs may increase CNS stimulation risk. Probenecid interferes with renal tubular secretion of ciprofloxacin. QT-prolonging agents (antiarrhythmics, antipsychotics, antidepressants) may have additive effects. Cyclosporine levels may increase requiring monitoring. Hypoglycemic agents may require dosage adjustment.

Missed dose

If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. Patients should never double the dose to make up for a missed administration. Maintaining consistent dosing intervals is crucial for maintaining therapeutic drug levels and preventing antibiotic resistance development. If multiple doses are missed, patients should contact their healthcare provider for guidance on resuming therapy.

Overdose

Symptoms of overdose may include nausea, vomiting, diarrhea, headache, dizziness, and tremors. More severe cases may involve seizures, confusion, and renal impairment. Management includes gastric lavage if presentation is early, followed by supportive measures. Hemodialysis removes approximately 10% of the drug and may be considered in severe cases. ECG monitoring is recommended to detect QT prolongation. Specific antidotes are not available, and treatment remains primarily supportive with attention to hydration status and renal function.

Storage

Store at controlled room temperature (20-25°C or 68-77°F) in the original container. Protect from light and excessive moisture. Keep tightly closed and out of reach of children. Do not store in bathroom cabinets where humidity levels fluctuate. Discard any medication that has expired or shows signs of physical deterioration. Do not transfer tablets to other containers as this may affect stability.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Healthcare professionals should consult official prescribing information before administering AlfaCip. Patients should not alter their dosage or treatment regimen without consulting their physician. The manufacturer is not liable for any adverse outcomes resulting from improper use of this medication. Always follow the guidance of qualified healthcare providers regarding diagnosis and treatment decisions.

Reviews

Clinical studies demonstrate AlfaCip achieves clinical cure rates of 85-95% for urinary tract infections and 80-90% for respiratory infections when pathogens are susceptible. Microbiological eradication rates typically exceed 90% for common uropathogens. Patient satisfaction surveys indicate high tolerability with appropriate management of gastrointestinal side effects. Medical professionals appreciate the predictable pharmacokinetics and reliable spectrum coverage, though most emphasize the importance of appropriate patient selection and monitoring for adverse effects.